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Huntington’s disease is an autosomal dominant neurodegenerative disease caused by abnormal polyglutamine expansion in hun-
tingtin (Exp-HTT) leading to degeneration of striatal neurons. Altered brain cholesterol homeostasis has been implicated in
Huntington’s disease, with increased accumulation of cholesterol in striatal neurons yet reduced levels of cholesterol metabolic
precursors. To elucidate these two seemingly opposing dysregulations, we investigated the expression of cholesterol 24-hydroxylase
(CYP46A1), the neuronal-speciﬁc and rate-limiting enzyme for cholesterol conversion to 24S-hydroxycholesterol (24S-OHC).
CYP46A1 protein levels were decreased in the putamen, but not cerebral cortex samples, of post-mortem Huntington’s disease
patients when compared to controls. Cyp46A1 mRNA and CYP46A1 protein levels were also decreased in the striatum of the R6/
2 Huntington’s disease mouse model and in SThdhQ111 cell lines. In vivo, in a wild-type context, knocking down CYP46A1
expression in the striatum, via an adeno-associated virus-mediated delivery of selective shCYP46A1, reproduced the Huntington’s
disease phenotype, with spontaneous striatal neuron degeneration and motor deﬁcits, as assessed by rotarod. In vitro, CYP46A1
restoration protected SThdhQ111 and Exp-HTT-expressing striatal neurons in culture from cell death. In the R6/2 Huntington’s
disease mouse model, adeno-associated virus-mediated delivery of CYP46A1 into the striatum decreased neuronal atrophy,
decreased the number, intensity level and size of Exp-HTT aggregates and improved motor deﬁcits, as assessed by rotarod and
clasping behavioural tests. Adeno-associated virus-CYP46A1 infection in R6/2 mice also restored levels of cholesterol and lanos-
terol and increased levels of desmosterol. In vitro, lanosterol and desmosterol were found to protect striatal neurons expressing
Exp-HTT from death. We conclude that restoring CYP46A1 activity in the striatum promises a new therapeutic approach in
Huntington’s disease.
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Introduction
Huntington’s disease is a dominantly inherited genetic dis-
ease characterized by an abnormal expansion of a CAG
trinucleotide repeat in the 5’ region of the huntingtin gene
(HTT) leading to a polyglutamine expansion in the hunting-
tin protein (Exp-HTT) (The Huntington’s Disease
Collaborative Group, 1993). Individuals with 36 CAG re-
peats or more in the HTT gene will develop clinical symp-
toms of Huntington’s disease including neuropsychiatric,
motor and cognitive deﬁcits (Aylward et al., 2000). Once
the ﬁrst symptoms have appeared, the disease progresses
and leads to death within 15 to 20 years. Brain atrophy
in Huntington’s disease predominates in the caudate-
putamen (striatum) and, to a lesser extent, in the cerebral
cortex.
Exp-HTT leads to many cellular dysfunctions, including
transcriptional dysregulation (Moumne´ et al., 2013),
altered energy metabolism (Cui et al., 2006; Tsunemi
et al., 2012), excitotoxicity (Milnerwood and Raymond,
2010), impaired axonal growth (Li et al., 2001) and trans-
port (Gauthier et al., 2004). It also induces protein aggre-
gation, a mechanism involved in several neurological
disorders, including Alzheimer’s disease and other CAG
repeat-associated diseases (Ross and Poirier, 2004). Each
of these cellular alterations can be involved, either separ-
ately or in concert, in striatal neuron dysfunction and death
(Roze et al., 2008a).
Huntington’s disease is also associated with abnormal-
ities in cholesterol metabolism (Karasinska et al., 2011;
Valenza et al., 2011), as observed in other neurodegenera-
tive diseases including Niemann-Pick disease Type C,
Smith-Lemli-Opitz (Korade and Kenworthy, 2008) and
Alzheimer’s disease (Puglielli et al., 2003; Shobab et al.,
2005). Cholesterol plays a critical role in brain develop-
ment, synaptogenesis, neuronal activity, and neuron sur-
vival (Bjorkem et al., 2004; Dietschy et al., 2004). In the
CNS, the blood–brain barrier is not permeable to choles-
terol and the brain sterol pool comes from in situ synthesis,
mostly from astrocytes (Pfrieger et al., 2003; Bjorkem et al.,
2004). Normal cholesterol levels are strictly maintained by
de novo synthesis and degradation and cells can sense their
level of cholesterol through the membrane-bound sterol
regulatory element-binding protein (SREBP) (Brown and
Goldstein, 1997). Brain cholesterol is catabolized to 24S-
hydroxycholesterol (24S-OHC) by the neuron-speciﬁc
enzyme CYP46A1 (Lund et al., 1999). 24S-OHC in turn
crosses the blood–brain barrier and is metabolized in the
periphery (Bjorkhem et al., 1997). Of note, cholesterol syn-
thesis is also inﬂuenced by BDNF, which stimulates the
transcription of enzymes involved in the cholesterol path-
way in neuronal, but not glial cells, in culture (Suzuki et al.,
2007; Valenza, 2007a, 2010). Hence, reduced transcription
and cortico-striatal release of BDNF may also account for
decreased striatal cholesterol synthesis in Huntington’s dis-
ease striatal neurons (Zuccato et al., 2001; Gauthier et al.,
2004). Finally it must be emphasized that Exp-HTT im-
pairs cholesterol metabolism and expression levels of
MBP in oligodendrocytes, which may account for develop-
mental myelination deﬁcits (Xiang et al., 2011).
Altered expression of a number of genes involved in chol-
esterol and fatty acid metabolism has been described for
Huntington’s disease cell lines and mouse models (Sipione
et al., 2002; Valenza et al., 2005; Valenza and Cattaneo,
2011). Enzymes involved in cholesterol biosynthesis, such
as HMG-CoAR, CYP51 (lanosterol 14-a demethylase) and
7-DHC (7-dehydrocholesterol reductase), show reduced ex-
pression in mouse models, along with decreased levels of
brain sterols, such as lanosterol and lathosterol. The levels
of 24S-OHC are also reduced in the plasma of patients
with Huntington’s disease (Leoni et al., 2008, 2013), and
in the brain of several yeast artiﬁcial chromosome (YAC)
and knock-in mouse models (Valenza et al., 2010).
Findings regarding cholesterol content in Huntington’s dis-
ease mouse models are less clear, with studies indicating
either a decrease (Valenza et al., 2007a, b, 2010), or an
accumulation (Trushina et al., 2006), depending on the
model and the methodology used (Marullo et al., 2012).
In the caudate of patients and in Huntington’s disease neur-
onal cell lines, cholesterol showed an accumulation (del
Toro et al., 2010). Therefore, increased cholesterol content
can persist in Huntington’s disease, despite reduced synthe-
sis. One important way to account for this apparent para-
dox is by reduced catabolism of cholesterol.
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In the present work, we show that the expression levels
of CYP46A1, the brain-speciﬁc rate-limiting enzyme in the
degradation of cholesterol (Lund et al., 1999; Bjorkhem
and Meaney, 2004), are decreased in the putamen of pa-
tients with Huntington’s disease, in the striatum of R6/2
mice, and in striatal Huntington’s disease cell lines. In vivo,
in a wild-type context, CYP46A1 knocking-down in the
mouse striatum, induced a decrease of 24S-OHC levels
and produced a spontaneous striatal neurodegeneration
associated to abnormal balance and motor coordination.
We further show that restoring CYP46A1 in vitro reduces
striatal neuron dysfunctions and aggregate formation. In
the R6/2 Huntington’s disease mouse model, adeno-asso-
ciated virus (AAV)-mediated delivery of CYP46A1 into
the striatum decreased neuronal atrophy and protein aggre-
gates and improved motor deﬁcits, as assessed by rotarod
and clasping behavioural tests. As expected, CYP46A1 res-
toration in the striatum of R6/2 mice increased 24S-OHC
levels. It also restored normal cholesterol and lanosterol
levels, and increased desmosterol, which proved to be neu-
roprotective. Hence, our study provides the ﬁrst evidence
that restoring normal levels of CYP46A1 may be neuropro-
tective in Huntington’s disease.
Materials and methods
Human extracts
Human brain samples were obtained from INSERM U289
Brain Bank at the Salpe´trie`re hospital (Paris) according to
standard legislation. Cerebral cortex and putamen samples
were obtained from ﬁve control subjects with no history of
neurological or psychiatric disorders (age: 72  7.3 years;
post-mortem delay: 10  1.78 h), and six patients with
Huntington’s disease clinically and neuropathologically diag-
nosed as grade 2, or 2/3 according to the classiﬁcation of
Vonsattel et al. (1985) (age: 64  3.38 years; post-mortem
delay: 25.7  6.08 h). These patients displayed choreic move-
ments at the end of the life.
Mice
Two-month-old female wild-type C57Bl/6 (Janvier) were used
(average weight 20–25 g). R6/2 [B6CBA-Tg (HDexon1)
62Gpb/1J] mice, which express exon 1 of the human mutant
Huntington’s disease gene containing 160 CAG repeats, under
the control of the human HTT (IT15) promoter, were obtained
from Jackson Laboratories by crossing ovarian transplant
hemizygous females with B6CBAFI/J males. All mice used in
the study were from the ﬁrst offspring and the genotype was
veriﬁed by polymerase chain reaction (PCR) using
genomic DNA extracted from tail. The number of CAG
repeat length varies very little in the progeny from the ﬁrst
generation (http://chdifoundation.org/wp-content/uploads/HD_
Field_Guide_040414.pdf), and can therefore be considered
around 160 CAG for all the mice that were used in the
study. The mice were housed in groups with a 12-h light/
dark cycle and provided with food and water ad libitum.
Animal care was conducted in accordance with standard eth-
ical guidelines (U.S. National Institutes of Health publication
no. 85–24, revised 1985, and European Committee Guidelines
on the Care and Use of Laboratory Animals) and the local
ethics committee approved the experiments.
RNA extraction and LightCycler
real time polymerase chain reaction
Mice were sacriﬁced by decapitation, and heads were snap
frozen in liquid nitrogen. Cerebral cortex, striata and hippo-
campus were punched on dry ice and stored at 80C until
RNA isolation. Samples were homogenized in QIAzol reagent
(Qiagen). RNA isolation was performed with RNeasy Lipid
Tissue Midi kit (Qiagen) according to manufacturer’s instruc-
tions. Reverse transcription was performed with Maxima First
Strand cDNA synthesis kit for RT-qPCR (Fermentas).
Quantitative real-time PCR reactions were performed using
LightCycler 480 SYBR Green I Master according to manu-
facturer’s protocol and run on LightCycler 480 (Roche
Diagnostics). Expression of hypoxanthine guanine phosphori-
bosyltransferase 1 (Hprt1) transcript was used to normalize
the cDNA amounts. The cycle threshold values were calculated
automatically by LightCycler 480 SW 1.5 software with de-
fault parameters. For primers sequences see the Supplementary
material.
Cultures of striatal neurons and
STHdh (Q111/Q7) striatal cells,
transfection, sterol treatment and
cell survival assays
Primary striatal neurons were dissected from Day 14 embryos
from pregnant Swiss mice (Janvier) as previously described
(Charvin et al., 2005; Deyts et al., 2009). After 7 days
in vitro, transient transfection of striatal cells was performed
with LipofectamineTM 2000 (Invitrogen). At this stage, very
few glial cells were observed (55%; data not shown). Green
ﬂuorescent protein (GFP)-tagged constructs encoding the ﬁrst
exon of human HTT containing either 25 (25Q-HTT) or 103
(103Q-HTT) continuous CAA or CAG repeats were provided
by the Huntington’s Disease Foundation Resource Bank,
UCLA, USA. The human CYP46A1 cDNA was tagged with
the haemagglutinin (HA) epitope (CYP46A1-HA).
Conditionally immortalized wild-type (STHdhQ7) and
mutant (STHdhQ111) striatal neuronal progenitor cell lines
expressing HTT with either seven or 111 glutamines were
grown as previously described (Gines et al., 2003). These
cells were transfected with cDNA encoding CYP46A1-HA
for 48 h, serum starved for 24 h and then ﬁxed with 4% par-
aformaldehyde in phosphate-buffered saline.
Endogenous mouse CYP46A1 was detected owing to im-
munocytochemistry with anti-rabbit CYP46A1 antibody
(1:1000, Abcam), neurons with anti-mouse MAP2 antibody
(1:1000, Millipore), CYP46A1-HA transfected neurons with
anti-rat HA antibody (1:1000, Roche). Appropriate anti-
rabbit, anti-mouse, or anti-rat cy3, cy5, Alexa Fluor 488
ﬂuorophore-conjugated secondary antibodies were used.
Lanosterol, desmosterol, cholesterol or 24S-OHC (1mM in di-
methyl sulphoxide) (Avanti Polar Lipids) was added for 48 h in
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the cell culture medium just after transfection. Nuclei were
stained with Hoechst 1:20 000.
Immunoblotting
Human brain samples were homogenized in NonidetTM P-40
lysis buffer (20mM Tris-HCl pH 7.5, 150mM NaCl, 2mM
EGTA, 1% NonidetTM P-40, 10mM b-glycerophosphate,
5mM NaF, 1mM NaPPi, 2mM dithiothreitol, 1mM sodium
vanadate, and 100mM PMSF) and cleared by centrifugation at
6000g (15min; 4C). Supernatants were collected and analysed
by sodium dodecyl sulphate-polyacrylamide gel electrophor-
esis. Mouse tissues and striatal cells were homogenized as pre-
viously described (Roze et al., 2008b). Primary antibody rabbit
polyclonal anti-CYP46A1 (1:1000) (Abcam), and mouse
monoclonal anti-b-tubulin 1:5000 (Sigma-Aldrich) were re-
vealed with appropriate anti-mouse or anti-rabbit peroxidase-
conjugated secondary antibodies (Jackson Laboratories) and
the ECL chemiluminescent reaction (Pierce).
Production and stereotaxic
injection of AAV5-GFPshCYP46A1,
AAV5-GFPshscramble, AAVrh10-
GFP and AAVrh10-CYP46A1
All AAV vectors were produced and puriﬁed by Atlantic Gene
therapies (Inserm U1089, Nantes, France). The viral constructs
AAV5-shScramble-GFP and AAV5-shCYP46A1-GFP con-
tained the expression cassette consisting of either short hairpin
(sh) CYP46A1 (shCyp46a1) or scrambled sequence
(shScramble), driven by a PU6 promoter and a GFP reporter
gene, driven by the phosphoglycerate kinase 1 (PGK1) pro-
moter in the AAV5 vector (Djelti et al., 2015). The viral con-
structs for AAVrh10-GFP and AAVrh10-CYP46A1-HA
contained the expression cassette consisting of either the GFP
or the human CYP46A1, driven by a CMV/b-actin hybrid
promoter (CAG) surrounded by inverted terminal repeats of
AAV2. The stereotaxic coordinates were: 0.5mm rostral to the
bregma, 2.1mm lateral to midline and 3.35mm ventral to the
skull surface. The rate of injection was 0.2 ml/min with a total
volume of 2 ml per striatum (equivalent to 3  109 genomic
particles).
Animal behaviour
The rotarod protocol was slightly adapted from Menalled
et al. (2009): mice were tested over three consecutive days,
each daily session included a 5min training trial at 4 rpm on
the rotarod apparatus. One hour later, the animals were tested
for three consecutive accelerating trials of 5min with the
rotarod speed linearly increasing from 4 to 45 rpm over
300 s. The latency to fall from the rod was recorded for
each trial. Mice remaining on the rod for more than 300 s
were removed and their time scored as 300 s. Data from the
training trial were not included. For hind limb clasping, mice
were tested once a week from 6 to 11 weeks old. They were
suspended by the tail for 30 s and the clasping phenotype was
graded according to the following scale: level 0, no clasping;
level 1, clasping of the forelimbs only or both fore- and
hindlimbs once or twice; and level 2, clasping of both fore-
and hindlimbs more than three times or more than 5 s.
Immunohistochemistry and
neuropathology
At the end of the behavioural studies, groups of mice were
rapidly anaesthetized by intraperitoneal injection of pentobar-
bital 250mg/kg (Sanoﬁ). Intracardiac perfusion of 4% paraf-
ormaldehyde in 0.1M Na2HPO4/NaH2PO4 buffer, pH 7.5
was performed and brains were post-ﬁxed overnight in the
same solution at 4C. Brain sections (30 mm) were incubated
with the following primary antibodies overnight: mouse-anti
NeuN (1:500; Millipore); mouse anti-HA (1:500; Covance),
mouse anti-DARPP32 (1/5000; generous gift from Pr P.
Greengard) and rabbit anti-expHTT (EM48) (1:1000;
Millipore). For immunoﬂuorescence, secondary antibodies
were incubated for 2 h: anti-mouse Alexa Fluor 488
(1:400), anti-rabbit Alexa Fluor 488 (1:400), anti-mouse
Alexa Fluor 568 (1:400), or anti-rabbit Alexa Fluor 546
(1:400; Invitrogen) in Tris-buffered saline. Sections were
mounted under cover slips using Vectashield (Vector
Laboratories). For 3,30 diaminobenzidine staining, the sections
were then incubated with anti-mouse biotinylated antibody
(1:250; Vector Laboratories Inc.) and visualized by the ABC
ampliﬁcation system (Vectastain ABC kit, Vector Laboratories)
and 3,30-diaminobenzidine tetrahydrochloride (peroxidase sub-
strate kit, DAB, Vector Laboratories) as the substrate.
A systematic evaluation of the transduced region was per-
formed by GFP ﬂuorescence (expression of shScramble or
shCYP46A1) or by haemagglutinin immunostaining (expres-
sion of CYP46A1 transgene). Adjacent sections were then
stained by Cresyl violet or immuno-labelled with NeuN,
DARPP-32 and EM48 antibodies, which are speciﬁc for neu-
rons, medium spiny neurons and Exp-HTT aggregates, respect-
ively. Sections were mounted under cover slips using
Vectashield (Vector Laboratories).
Image acquisition
For DARPP32 depletion studies in shCYP46A1 experiments,
images of immunostained sections were acquired with LAS
V3.8 (Leica) software, with a bright-ﬁeld Leica DM 4000B
microscope equipped with 40 /0.75 and 100 /1.30 lenses
and a Leica DFC500 digital camera. Confocal images were
acquired with an Olympus BX 61 microscope equipped with
60 /1.35 lens and Fluoview FV-1000 image acquisition
system. The extent of shCYP46A1-induced lesions in the stri-
atum was analysed in six DARPP32-stained sections per
animal (320 mm between 40-mm thick sections), selected to
obtain a complete rostrocaudal sampling of the striatum and
by quantifying the area of the lesion with a semi-automated
image-analysis program (ImageJ software, NIH). Sections
throughout the entire striatum were analysed. The area of
the striatum showing a loss of DARPP32 staining was mea-
sured for each animal with an operator-independent macro.
The volume was then estimated using the following formula:
volume = d(a1 + a2 + a3 +   ), where d is the distance be-
tween serial sections (320 mm), and a1, a2, a3 etc. are
DARPP32-depleted areas for individual serial sections. The
average grey value of all pixels measured in the lesioned
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area was recorded for each depleted area. Results are pre-
sented as the calculated value for volume of the DARPP32
depleted region for each animal.
For studies in R6/2 mice, the analysis of DARPP32 and
EM48 staining, images were acquired from a confocal laser
scanning microscope (TCS, SP5, Leica Microsystems).
DARPP32-stained neurons were manually traced and MSN
area quantiﬁed using ImageJ software. For the counting of
aggregates, EM48-stained images were segmented using the
same global threshold and quantiﬁed using ImageJ software.
An x, y pixel size of 150 nm and a z-step of 500 nm were
chosen, laser intensity and detector gain were constant for
all images. Aggregates were segmented in 3D using the same
global threshold. The ImageJ plugin 3D object counter was
used to measure volume and mean intensity of each aggregate.
For each aggregate, mean intensity is the mean of all voxel
intensities in an 8-bit scale.
Cholesterol and oxysterol
measurements
Cholesterol and oxysterol analysis followed the ‘gold standard’
method (Dzeletovic et al., 1995) to minimize the formation of
autoxidation artefacts. Brieﬂy, mouse striatal tissue samples
were weighed and homogenized with a TissueLyser II appar-
atus (Qiagen) in a 500ml solution containing butylated hydro-
xytoluene (BHT, 50 mg/ml) and EDTA (0.5 M). At this point, a
mix of internal standards was added [epicoprostanol, 2H7-7-
lathosterol, 2H6-desmosterol,
2H6-lanosterol and
2H7-24(R/S)-
hydroxycholesterol] (Avanti Polar Lipids). Alkaline hydrolysis
was performed under Ar using 0.35 M ethanolic KOH for 2 h
at room temperature. After neutralization of the solution with
phosphoric acid, sterols were extracted in chloroform. The
lower phase was collected, dried under a stream of nitrogen
and the residue was dissolved in toluene. Oxysterols were then
separated from the cholesterol and its precursors on a 100mg
Isolute silica cartridge (Biotage); cholesterol was eluted in
0.5% propan-2-ol in hexane followed by oxysterols in 30%
propan-2-ol in hexane.
The sterol and oxysterol fractions were independently sily-
lated with Regisil + 10% TMCS [bis(trimethylsilyl) triﬂuoro-
acetamide + 10% trimethylchlorosilane] (Regis technologies) as
described previously (Chevy et al., 2005). The trimethylsilylether
derivatives of sterols and oxysterols were separated by gas chro-
matography (Hewlett-Packard 6890 series) in a medium polar-
ity capillary column RTX-65 (65% diphenyl 35% dimethyl
polysiloxane, length 30m, diameter 0.32mm, ﬁlm thickness
0.25mm; Restesk). The mass spectrometer (Agilent 5975 inert
XL) in series with the gas chromatography was set up for de-
tection of positive ions. Ions were produced in the electron
impact mode at 70 eV. They were identiﬁed by the fragmento-
gram in the scanning mode and quantiﬁed by selective monitor-
ing of the speciﬁc ions after normalization and calibration with
the appropriate internal and external standards [epicoprostanol
m/z 370, 2H7-7-lathosterol m/z 465,
2H6-desmosterol m/z 358,
2H6-lanosterol m/z 504,
2H7-24(R/S)-hydroxycholesterol m/z
553, cholesterol m/z 329, 7-lathosterol m/z, 7-dehydrocholes-
terol m/z 325, 8-dehydrocholesterol m/z 325, desmosterol m/z
343, lanosterol m/z 393 and 24(R/S)-hydroxycholesterol m/z
413].
Statistical analysis
Statistical analyses were performed with GraphPad Prism 5.
All data are represented as mean  SEM. For studies on ex-
pression levels in Huntington’s disease patient tissues, R6/2
mice and striatal neurons in culture, the signiﬁcance was as-
sessed by unpaired Student’s t-test with Welch correction. For
survival studies in vitro, one-factor ANOVA corrected by the
post hoc Bonferroni test was performed. For behavioural stu-
dies and neuronal areas in mice, a non-parametric two-way
ANOVA analysis corrected by the post hoc Bonferroni was
performed with time and treatment as independent factors.
For mass spectrometry and aggregate studies, Mann-Whitney
test was applied.
Results
CYP46A1 expression levels are
reduced in Huntington’s disease
To evaluate the relevance of CYP46A1 in the context of
Huntington’s disease, we analysed its protein expression
levels in post-mortem samples of striatum, which comprises
caudate nucleus and putamen, the most severely affected
region in Huntington’s disease. By immunoblotting the
samples with an antibody against CYP46A1, and anti-b-
tubulin as a control of protein loading, we found a signiﬁ-
cant reduction of CYP46A1 over anti b-tubulin ratio
(44%) in the putamen of patients with Huntington’s dis-
ease when compared with control individuals (Fig. 1A and
B). This reduction was not observed in cortex samples of
Huntington’s disease patients (Fig. 1A and B). The post-
mortem samples came from symptomatic patients (grade
2, 2/3). However, no signiﬁcant modiﬁcation in the levels
of calbindin, a selective marker of medium spiny neurons,
were found in these extracts (Benchoua et al., 2006) indi-
cating that reduced CYP46A1 expression levels in post-
mortem putamen tissues are not merely a reﬂection of cell
death. Microarray data from human samples (caudate) of
pathological grade 0–2 previously showed that transcripts
for CYP46A1 were reduced when compared to control
patients (Kuhn et al., 2007). Altogether, these data strongly
support that reduced CYP46A1 protein levels result from
transcriptional dysregulation, which occurs as a conse-
quence of Exp-HTT.
We next studied CYP46A1 levels in the R6/2 transgenic
Huntington’s disease mouse model, which expresses the ﬁrst
exon of the human gene containing 150 CAGs. Cyp46A1
mRNA levels were decreased in the striatum and cortex at 6
weeks (40% and 32%, respectively) and 12 weeks
(69% and 59%, respectively) (Fig. 1C and D), but not
in the hippocampus. Decreased CYP46A1 protein levels
(37% and 41%, respectively) were found in these brain
areas at 12 weeks (Fig. 1E).
We next used immortalized wild-type (STHdhQ7) and
mutant (STHdhQ111) striatal neuronal progenitor cell
lines expressing HTT with either seven or 111 glutamines,
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respectively (Gines et al., 2003). The STHdhQ111 striatal
cell line that expresses most of the cellular characteristics
of Huntington’s disease (Trettel et al., 2000), also showed
a signiﬁcant reduction of CYP46A1 mRNA (Fig. 1F) and
protein (Fig. 1G) levels when compared to STHdhQ7 striatal
cells with seven CAG repeats. To determine the impact of
CYP46A1 deﬁciency in Huntington’s disease, we measured
cholesterol and 24S-OHC in the striatum of R6/2 mice (12
weeks old). We found a 1.5-fold increase of cholesterol in
the striatum (Fig. 1H), therefore reproducing previous ob-
servations in the caudate of patients with Huntington’s dis-
ease (Del Toro et al., 2010). Comparison of cellular
Figure 1 CYP46A1 expression levels in human, R6/2 mice and striatal cell lines. (A) Cortex and putamen extracts from control
(n = 5) and Huntington’s disease patients (cortex n = 5, putamen n = 6) were processed for western blotting with antibodies directed against
CYP46A1 and b-tubulin. (B) Quantification of CYP46A1 protein levels normalized to b-tubulin from western blots in (A). (C and D) Cyp46a1
transcript levels were measured by quantitative PCR relative to Hprt from wild-type (WT, n = 6) and R6/2 (n = 5) mice. Ctx = cortex,
Hpc = hippocampus, St = striatum at 6 (C) or 12 (D) weeks (wk) of age. (E) Top: Extracts from wild-type and R6/2 mice at 12 weeks of age were
processed for western blotting with CYP46A1 and b-tubulin antibodies. Bottom: Quantification of CYP46A1 protein levels normalized to b-tubulin
from wild-type (n = 3) and R6/2 (n = 5) extracts. (F) Cyp46a1 transcript levels from STHdhQ7 (Q7) and STHdhQ111 (Q111) striatal cell line
(n = 5). (G) Top: Western blotting with CYP46A1 and b-tubulin from Q7 and Q111. Bottom: Quantification of CYP46A1 protein levels normalized
to b-tubulin from Q7 and Q111 extracts (n = 6). (H) Cholesterol and 24S-OHC levels were measured in striatum from wild-type and R6/2 at 12
week of age. (B–G) All data are represented as mean  SEM; statistical analysis: unpaired Student’s t-test. *P5 0.05; **P5 0.01; ***P5 0.001. (H)
Data are shown as a box plot. Statistics Mann-Whitney test **P5 0.01; for wild-type versus R6/2 mice. HD = Huntington’s disease.
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cholesterol localization in the striatum of wild-type and R6/2
mice was assessed by ﬁlipin staining, a naturally ﬂuorescent
polyene probe that binds to cholesterol but not to esteriﬁed
sterols. Cholesterol labelling showed a marked staining of
plasma membrane in both wild-type and R6/2 striatal cells.
Cholesterol accumulation in internal organelles was not
observed in R6/2 mice (Supplementary Fig. 1). Despite
decreased expression of CYP46A1, 24S-OHC was not
altered in the striatum of R6/2 mice (Fig. 1H).
Altogether, these data indicate that CYP46A1 levels are
reduced in the striatum from Huntington’s disease patients,
mouse and cellular models.
CYP46A1 knock-down in a wild-type
context induces a Huntington’s
disease-like phenotype
To assess the impact of CYP46A1 deﬁciency in a wild-type
context, we used a shRNA sequence that was shown to
inhibit CYP46A1 expression in vitro and in vivo (Djelti
et al., 2015). Two-month-old mice were bilaterally injected
into the striatum with either AAV5-shCyp46A1-GFP or
AAV5-shScramble-GFP (control sequence that does not
target Cyp46a1 mRNA sequence) (Fig. 2A). A GFP tag
was used as a marker of viral infection. To evaluate
whether the deﬁciency in CYP46A1 could be translated
into behavioural dysfunction, the animals (n = 7 for
shCyp46a1 and n = 8 for shScramble) underwent a test of
balance and motor coordination—the rotarod—at 3
months post-injection. All C57 mice had similar perform-
ances in rotarod before the viral infections. Three months
post-injection, shCYP46A1-injected mice had a signiﬁcant
decrease in their latency to fall when compared to
shScramble-injected mice (Fig. 2B), and their weight was
signiﬁcantly reduced (16%) (Fig. 2C). These mice were
then sacriﬁced, and one striatum from each mouse was
extracted, immediately frozen and used to measure 24S-
OHC levels by mass spectrometry. A 50% reduction in
the levels of 24S-OHC was found in the striata of
shCYP46A1-injected mice, relative to striata of
shScramble-injected mice (Fig. 2D), thus indicating that
shCYP46A1 was efﬁcient in reducing CYP46A1 activity.
The second brain hemisphere was ﬁxed and processed for
neuropathological studies including Cresyl violet staining
(Fig. 2E), DARPP32 (Fig. 2F) and NeuN (Fig. 2G) im-
munocytochemistry. Cresyl violet staining indicated
increased condensed nuclei (degeneration) in the
shCYP46A1-injected compared to shScramble-injected
striata, where minimal condensed nuclei were observed
around the needle tract region (Fig. 2E). DARPP32 (a se-
lective marker of medium spiny neurons) immunostaining
showed a strong depletion in the striatum of shCYP46A1
injected mice, whereas no DARPP-32 loss was observed in
shScramble injected mice (Fig. 2F and G). Then we used
immunodetection of NeuN (a neuronal marker) and found
a strong decrease in animals injected with shCYP46A1
when compared to shScramble (Fig. 2H). Altogether these
data indicate that motor dysfunction and neuronal death
occurred as a consequence of CYP46A1 deﬁciency.
CYP46A1 restoration protects from
Exp-HTT-induced striatal dysfunc-
tions in vitro
We then asked whether CYP46A1 restoration could protect
from striatal neuron dysfunctions induced by Exp-HTT.
Primary striatal neurons in culture were transiently trans-
fected with cDNAs encoding the ﬁrst exon of HTT con-
taining either 25 (25Q-HTT) or 103 (103Q-HTT) CAG
repeats, and fused to the GFP coding sequence.
Expression levels of CYP46A1 were decreased in 103Q-
HTT- when compared to 25Q-HTT-transfected neurons
or non-transfected neurons (Fig. 3A). 103Q-HTT-express-
ing neurons showed decreased survival (34%, evaluated
by nuclear morphology after Hoechst staining) 48 h after
transfection (Fig. 3B and C). When striatal neurons were
co-transfected with cDNAs encoding 103Q-HTT and a
CYP46A1-HA, a signiﬁcant neuroprotection was found
(55% versus 79%) (Fig. 3B and C). CYP46A1-HA over-
expression also resulted in a signiﬁcant reduction of 103Q-
HTT-induced aggregate formation (58% versus 27%) (Fig.
3B and D).
For the STHdhQ111 striatal cell line, which shows
higher susceptibility than STHdhQ7 under serum depriv-
ation (Tourette et al., 2014), CYP46A1-HA was also neu-
roprotective (Fig. 3E). A lower percentage of picnotic nuclei
was found in STHdhQ111 transfected with CYP46A1-HA
when compared to STHdhQ111 control cells (2.67%
versus 10.63%) (Fig. 3E).
Taken together, these results are consistent with a neuro-
protective role for CYP46A1 against Exp-HTT-induced
striatal dysfunction.
CYP46A1 restoration in the striatum
improves the motor phenotype
of R6/2 mice
Next we investigated a possible neuroprotective role for
CYP46A1 in vivo. We used AAVrh10 for CYP46A1 deliv-
ery in the striatum of mice. AAVrh10 shows widespread
transduction efﬁciency and a strong level of gene expression
in the striatum (Sondhi et al., 2007) (see also Supplementary
Fig. 2B and C). AAVrh10 encoding CYP46A1-HA was in-
jected bilaterally in the striatum of 4-week-old R6/2 mice
(Fig. 4A). Three weeks later, haemagglutinin immunolabel-
ling showed widespread expression in the dorsal striatum
(Fig. 4B). Double labelling showed no expression of
CYP46A1-HA in astrocytes (GFAP), microglia (isolectin),
or oligodendrocytes (OLIG2) (Supplementary Fig. 2D). In
contrast, we found perfect co-localization in neuronal cells
(NeuN, Supplementary Fig. 2D). In addition, Cyp46a1
mRNA levels were rescued on CYP46A1-HA injection in
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Figure 2 ShCYP46A1 produces spontaneous motor deficits and striatal neuron dysfunctions in a wild-type context. (A) Two-
month-old C57BL6J mice were stereotactically injected in the striatum with either AAV5-GFP-shCyp46A1 or AAV5-GFP-shScramble (control
sequence that does not target Cyp46a1 mRNA). (B) All mice (n = 8 for each group) were blindly submitted to behavioural experiments. The
Rotarod test used to evaluate mouse balance and coordination revealed that the latency to fall was decreased in mice injected with shCYP46A1,
compared to shScramble-injected mice. (C) Two months later, the weight of mice injected with shCYP461 showed a statistically significant
reduction at the time of sacrifice (16%). (D–G) Mice were sacrificed 3 months later and for each mouse, the striatum from one hemisphere was
processed for biochemical studies while the other was used for neuropathological studies. (D) 24S-OHC measurements were performed by mass
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these mice (Supplementary Fig. 3). Therefore, this approach
was deemed appropriate for further in vivo studies.
The R6/2 mouse model recapitulates many features of the
human disease, including motor impairment appearing before
the age of 6 weeks (Menalled et al., 2009). Thus, the early
and reproducible phenotype of this mouse line has made it an
ideal model for screening compounds, performing genetic
crosses, and testing gene therapy approaches. No signiﬁcant
improvement in body weight was observed in R6/2 mice in-
jected with AAVrh.10-CYP46A1-HA (CYP46A1-HA R6/2
mice; Supplementary Fig. 4). Neurological performance,
tested using the Rotarod test, reliably declined in control
R6/2 mice (saline or AAVrh10-GFP injected) as assessed
every week from 6 to 11 weeks of age (Fig. 4C and D). In
CYP46A1-HA R6/2 mice no signiﬁcant improvement in per-
formance was observed 2 weeks after injection (Fig. 4C and
D). However, although this behaviour progressively declined
from 7 to 11 weeks in control R6/2 mice, it remained stable
in CYP46A1-HA injected R6/2 mice from 6 to 11 weeks
(Fig. 4C and D). A signiﬁcant difference in the latency to
fall was measurable between R6/2 mice and CYP46A1-HA
R6/2 mice from 8 to 11 weeks.
Abnormal hind limb clasping is reminiscent of dystonic
movements in mouse models of Huntington’s disease (Stack
et al., 2005; Bauer et al., 2010; Paul et al., 2014). The clasp-
ing test assessed the presence of dystonic movements that
occur during 30 s of tail suspension (hind limb splay, limb
clasping and sustained limb ﬂexure). A gradual score was
established to evaluate the progressive severity of this
motor disturbance. While all wild-type mice showed normal
hind limb splay, R6/2 mice exhibited progressive limb clasp-
ing by 6 weeks that became more pronounced with age, with
sustained ﬂexure of both forelimbs and hind limbs (Fig. 4E
and F). CYP46A1-HA R6/2 mice showed markedly lower
clasping scores until 10 weeks old (Fig. 4F).
Altogether, these data indicate that CYP46A1-HA restor-
ation delays progressive deterioration of motor perform-
ance in R6/2 mice.
CYP46A1 restoration protects R6/2
mice from neuropathological
alterations
Twelve week old mice were sacriﬁced for neuropathological
studies. Cresyl violet staining showed a global cellular
atrophy in the striatum of R6/2 mice (Stack et al., 2005),
which was positively impacted by CYP46A1-HA
(Supplementary Fig. 5). Medium spiny neuron atrophy
can be detected owing to DARPP32 immunocytochemistry
(Bibb et al., 2000). Double immunostaining with DARPP32
and haemagglutinin showed pronounced medium spiny
neuron atrophy in control R6/2 when compared to wild-
type mice, and CYP461-HA signiﬁcantly improved medium
spiny neuron area (59 mm2 versus 74mm2, respectively; Fig.
5B and C) and DARPP32 staining.
The formation of intracellular aggregates composed pri-
marily of Exp-HTT is a common pathological hallmark of
Huntington’s disease, and can be found in R6/2 mice
(Davies et al., 1997). To determine whether CYP46A1 re-
duces aggregate load, striatal sections were stained with
EM48 antibody, which speciﬁcally labels Exp-HTT aggre-
gates. EM48-positive foci were counted in striatal areas
that expressed CYP46A1-HA (Fig. 5C) and their quantiﬁ-
cation was normalized to control R6/2 mice (Fig. 5D).
CYP46A1-HA R6/2 mice showed a signiﬁcant decrease in
the number of aggregates (40%) when compared with
control R6/2 mice. By contrast, non-transduced cortical
area did not show any differences in aggregate number
(Supplementary Fig. 5). The mean intensity of Exp-HTT-
induced aggregate formation decreased in CYP46A1-HA
R6/2 mice (Fig. 5E and F). After Hoechst counterstaining,
aggregates were found as nuclear inclusions in control R6/2
mice (97.3  3.2%). CYP46A1-HA expression did not
modify this nuclear localization of aggregates
(97.8  2.8%) (Fig. 5G). However, the mean volume of
aggregates was signiﬁcantly lower in CYP46A1-HA R6/2
as compared to control R6/2 mice (Fig. 5H and I).
Collectively, these data reveal that CYP46A1 reduces the
number, intensity level and size of aggregates.
Regulation of cholesterol homeosta-
sis by CYP46A1
Quantitative measurements of sterols and oxysterols were
performed by mass spectrometry from striatal extracts. We
ﬁrst compared cholesterol and 24S-OHC levels of wild-type
and R6/2 mice injected or not with AAVrh10-GFP into the
striatum (Supplementary Fig. 6). No signiﬁcant differences
were found between wild-type or R6/2 mice injected with
saline or AAV-GFP, indicating that the AAVrh10 vector by
itself does not alter cholesterol homeostasis.
Figure 2 Continued
spectrometry. A 50% reduction in the levels of 24S-OHC was shown in the striatum of shCYP46A1-injected mice, relative to shScramble-
injected mice. (E) Cresyl violet staining from striata injected with shScramble (top) and shCYP46A1 (bottom). Note the increased condensed
nuclei (degeneration) in the striatum injected with shCyp46A1 when compared to shScramble, where minimal condensed nuclei were observed
around the needle tract region. (F) DARPP32 immunostaining shows a strong depletion in the striatum of shCYP46A1 injected mice (lower panel),
when compared to shScramble injected mice. (G) Quantification of DARPP32 depleted area (n = 6 for each group). (H) Co-labelling of GFP (used
as a tag for shRNA sequences) and NeuN immunostaining shows a strong co-localization (merge panel) in shScramble injected neurons. In
contrast, no co-localization is observed between GFP and NeuN in animals injected with shCYP46A1, indicating neuronal dysfunction in the
transduced area. (B–G): Data are represented as mean  SEM; statistical analyses: Mann whitney’s test. *P5 0.01; **P5 0.05; ***P5 0.001
shScramble versus shCYP46A1. WT = wild-type.
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Figure 3 CYP46A1 decreases 103Q-HTT-induced toxicity in primary striatal neurons and STHdhQ111 striatal cells. (A) Striatal
neurons were transfected with plasmids coding for either 25Q-HTT or 103Q-HTT. Transfected neurons were revealed after fixation 24 h later
by GFP staining (green), and co-labelled after CYP46A1 (orange), MAP2 (red) immunostaining, and Hoechst staining (blue). White arrow indicates
transfected neuron (25Q top, 103Q bottom), that is shown at higher magnification in the insert. Note in the merge panel that CYP46A1 signal
is decreased in 103Q-HTT expressing neurons when compared to 25Q-HTT-transfected neurons. Scale bar = 20 mm. (B) Striatal neurons were
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We then analysed the cholesterol metabolism of wild-type
and R6/2 mice injected or not with CYP46A1-HA (Fig. 6).
Lanosterol, the ﬁrst sterol of the metabolic pathway, along
with cholesterol intermediates from the Kandutsch-Russell
(lathosterol) and Bloch (desmosterol) pathways were ana-
lysed. As previously described, lanosterol levels were
decreased in the striatum of R6/2 mice (Valenza et al.,
2005, 2010) (Fig. 6A), and 24S-OHC levels were unchanged
(Valenza et al., 2007b), although reduced levels have also
been observed (Valenza et al., 2010). The level of lathos-
terol, a common surrogate marker of cholesterol biosynthe-
sis (Kempen et al., 1988), was signiﬁcantly lowered in R6/2
mice (Fig. 6B), while the desmosterol content remained un-
changed (Fig. 6C). In CYP46A1-HA R6/2 mice, normal
levels of lanosterol were restored (Fig. 6A), with no
change in lathosterol (Fig. 6B), and dramatical increase in
desmosterol content (Fig. 6C). CYP46A1 restoration also
resulted in normal cholesterol concentration (Fig. 6D) and
increased 24S-OHC levels (Fig. 6E) in the striatum of R6/2
mice. None of these recoveries were linked to transcriptional
regulation of the corresponding sterol synthesis enzymes
(Supplementary Fig. 7). Together, these data indicate that
restoration of CYP46A1 reinstates normal cholesterol
levels by increasing cholesterol degradation and by increas-
ing lanosterol and desmosterol levels.
Protection by lanosterol and
desmosterol in Huntington’s disease
striatal neurons
To study a potential neuroprotection of sterols and oxy-
sterol regulated or produced by CYP46A1, i.e. cholesterol,
lanosterol, desmosterol and 24S-OHC, we used striatal
neurons in culture expressing Exp-HTT. The effect of
these compounds was evaluated 48 h after exposure
(Fig. 6F). Survival was not modiﬁed by either cholesterol
or 24S-OHC treatments (49.95% and 61.49%, respect-
ively) as compared to control (53.9%), but was signiﬁ-
cantly improved by lanosterol and desmosterol ( +11.56%
and +13.57%, respectively). These data indicate that lanos-
terol and desmosterol can be neuroprotective in striatal
neurons expressing Exp-HTT.
Discussion
Cholesterol disturbance in Huntington’s disease has re-
cently emerged as an important ﬁeld of investigation.
Both decreased sterol synthesis and increased neuronal ac-
cumulation of cholesterol have been observed, yet the cel-
lular mechanisms accounting for this apparently opposing
dysregulation in cholesterol homeostasis has not been well
studied. We found that the expression of CYP46A1, the
rate-limiting enzyme for cholesterol degradation in the
brain (Lund et al., 1999; Bjorkhem and Meaney, 2004),
is decreased in the putamen of patients with Huntington’s
disease, in the striatum of R6/2 mice, and in Huntington’s
disease striatal cell lines. In vivo, in a wild-type context,
CYP46A1 knock-down induced motor deﬁcits and spon-
taneous striatal neuron death. We further show that restor-
ing CYP46A1 levels protected against Exp-HTT-induced
striatal dysfunctions in vitro, including aggregate formation
and neuronal death. In vivo, restoring CYP46A1 in the
striatum of the Huntington’s disease R6/2 mouse model
alleviated motor deﬁcits, improved medium spiny neuron
size, and restored cholesterol homeostasis. We conclude
that this enzyme plays a neuroprotective role in
Huntington’s disease.
Transcriptional dysregulation is an important event in the
neuropathological process in Huntington’s disease
(Moumne´ et al., 2013). A global microarray study from
mouse models (R6/2 and knock-in mice) and samples
from post-mortem human Huntington’s disease caudate
previously showed downregulation of Cyp46A1 transcripts
(Kuhn et al., 2007). Herein, we further show that Cyp46A1
transcripts are reduced in the striatum of R6/2 mice and
with STHdhQ111 striatal cell lines. Altered histone acetyl-
ation levels and binding of the SP1 transcription factor to
the promoter of Cyp46A1 (Nunes et al., 2010) could be
responsible for Cyp46A1 dysregulation by Exp-HTT, as
previously shown for other genes (Dunah et al., 2002;
Sadri-Vakili et al., 2007).
In agreement with previous studies (Trushina et al., 2006;
Valenza et al., 2007a, b, 2010; del Toro et al., 2010), we
found decreased levels of lanosterol and lathosterol and a
slight increase in cholesterol levels in the striatum of R6/2
mice. Although 24S-OHC plasma levels are reduced in pa-
tients with Huntington’s disease and parallels the degree of
caudate atrophy (Leoni et al., 2013), we failed to detect
any variation of 24S-OHC in the striatum, as previously
described (Valenza et al., 2007b). Altogether our data sug-
gest that altered cholesterol homeostasis in Huntington’s
disease appears as a consequence of decreased sterol
biosynthesis, and dysregulation of cholesterol clearance,
occurring as a consequence of CYP46A1 deﬁciency.
Importantly, increased expression of CYP46A1 restored
Figure 3 Continued
co-transfected with either 25Q-HTTor 103Q-HTT (GFP, green) in the presence or not of HA-CYP46A1. Haemagglutinin (HA, red) and Hoechst
(blue) stainings were performed 48 h later after fixation for detection of transfected neurons and nuclear labelling, respectively. Scale bar = 40 mm.
(C) Quantification of surviving transfected neurons based on nuclear integrity after Hoechst labelling and (D) quantification of aggregates based
on GFP fluorescence. (E) STHdhQ7 and Q111 striatal cell lines were transfected with plasmids coding CYP46A1-HA and serum starved for 24 h.
(B–D) Data were analysed from at least three independent experiments (100 transfected neurons per condition and per experiment) and
expressed as mean  SEM. One-factor analysis of variance (ANOVA) corrected by the Bonferroni’s post hoc test was performed.*P5 0.05;
**P5 0.01; ***P5 0.001.
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Figure 4 Striatal injection of AAV-rh10-CYP46A1-HA improves behavioural phenotypes in R6/2 mice. (A) Stereotaxic injection
of AAVrh10-CYP46A1-HA was performed at 4 weeks in the striatum, according to the indicated coordinates (AP = antero-posterior;
ML = medio-lateral; and DV = dorso-ventral), and sacrificed 3 weeks later. (B) Haemagglutinin (HA) immunostaining was performed on a sagittal
section from 7-week-old mice. Note the widespread expression of CYP46A1-HA within the striatum (Ctx = cortex; Cc = corpus callosum;
St = striatum). Scale bar = 440 mm. (C and D) Rotarod performance of wild-type and R6/2 mice injected with saline, AAVrh10-GFP or AAVrh10-
CYP46A1-HA. (C) Latency to fall was measured from 6 to 11 weeks for each group. (D) Rotarod speed when mice fall. (E) Representative
pictures of postures in wild-type (WT, top) or R6/2 (bottom) injected with saline (left) or AAVrh10-CYP46A1-HA (right; CYP46A1-HA) during tail
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normal cholesterol levels. The synthesis of new cholesterol
and the production of 24S-OHC are closely related.
Accordingly, a signiﬁcant reduction of cholesterol synthesis
was found in brain samples from CYP46A1 knockout
mice, despite stable steady state levels of cholesterol
(Lund et al., 2003). Although cholesterol is important for
neuronal integrity in physiological context, its accumula-
tion in membrane is deleterious. In the context of
Huntington’s disease, Exp-HTT favours cholesterol accu-
mulation in membranes, despite its decreased synthesis
(Trushina et al., 2006, 2014; del Toro et al., 2010). This
accumulation is thought to modify intracellular signalling
of downstream neurotransmitter receptors distributed in
lipid rafts. Within lipid rafts Exp-HTT accumulates with
the active-phosphorylated form of glycogen synthase
kinase-3b (GSK-3b, encoded by GSK3B), a pro-apoptotic
kinase whose activity can be attenuated by cholesterol de-
pletion (Valencia et al., 2010). GSK-3b inhibitors reduce
death of Exp-HTT-expressing neurons, suggesting that
GSK-3b activity contributes to neuronal death in
Huntington’s disease. In hippocampal neurons, CYP46A1
over-expression depletes membrane cholesterol (Martin
et al., 2008) thereby increasing the pro-survival signalling
pathway involving downstream BDNF receptors. In con-
trast, CYP46A1 loss of function decreases TrkB phosphor-
ylation. Therefore the neuroprotective effect of CYP46A1
observed in the context of Huntington’s disease could rely
on regulation of normal membrane cholesterol levels along
with pro-survival intracellular pathways. Cholesterol con-
tent impacts the composition and organization of the syn-
aptic membrane, and thus regulates the lateral diffusion of
molecules and ultimately the stability and plasticity of neur-
onal synapses (Renner et al., 2009).
Two alternative pathways for cholesterol synthesis exist
downstream of lanosterol (Fig. 7): the Bloch (desmosterol)
and the Kandutsch-Russel (lathosterol) pathways. In cell
cultures, the Bloch pathway is preferentially used in astro-
cytes to efﬁciently produce cholesterol (Nieweg et al.,
2009), while the Kandutsch-Russel pathway is used in neu-
rons, but produces cholesterol with much less efﬁciency.
The increase in desmosterol produced by CYP46A1 expres-
sion probably results from regulatory events between neur-
onal and glial cells. However, neuronal restoration of
CYP46A1 failed to change lathosterol levels, suggesting
that CYP46A1 regulates cholesterol homeostasis preferen-
tially through the Bloch pathway.
Both lanosterol and desmosterol were protective in pri-
mary culture of striatal neurons expressing Exp-HTT.
Neuroprotection by lanosterol was recently proposed in
Parkinson’s disease. Similar to Huntington’s disease, lanos-
terol is decreased in a Parkinson’s disease mouse model and
is neuroprotective in vitro for MPP+-treated dopaminergic
neurons, likely by promoting mitochondria uncoupling
and autophagy (Lim et al., 2012). Increasing autophagy,
which is known to favour Exp-Htt clearance, is neuropro-
tective in Huntington’s disease (Martin et al., 2015).
Neuroprotection by desmosterol has yet to be reported,
although it is known to suppress proinﬂammatory gene
expression in macrophage foam cells (Spann et al., 2012).
Early inﬂammatory reactions, such as reactive microglia
and elevated cytokine levels, are observed in the brains of
patients with Huntington’s disease as well as mouse models
(Sapp et al., 2001). Taken together, lanosterol and desmos-
terol could be neuroprotective by acting on mitochondria,
autophagy and inﬂammatory response that are impaired in
Huntington’s disease.
Central regulators of cholesterol metabolism in mammals
include the nuclear liver X receptors (LXRs) that bind the
promoters of cholesterogenic enzymes (Karazinska et al.,
2011). 24S-OHC is classically described as an endogenous
regulator of LXR-target genes in vitro (Brown and
Goldstein, 1997; Leoni and Caccia, 2015). However,
LXR target genes were not upregulated in transgenic mice
that overexpress brain CYP46A1 (Shafaati et al., 2011) or
in the hippocampus of Alzheimer mice injected with AAV-
CYP46A1 (Hudry et al., 2010). Accordingly, we failed to
detect any regulation of these genes on restoration of
CYP46A1 in vivo, likely owing to the diversity of cellular
populations and the complexity of CYP46A1-mediated ef-
fects in neuronal versus glial cells. It is noteworthy that
CYP46A1 strongly decreased Exp-HTT-induced aggregate
formation both in vitro and in vivo. Interestingly, 24S-
OHC regulates the expression of glucose-regulated protein
78 (GRP78, encoded by hspa5), an endoplasmic reticulum
chaperone that counteracts aggregation of Exp-HTT (Jiang
et al., 2012) and reduces amyloid-b production in a mouse
model of Alzheimer disease (Urano et al., 2013). Therefore,
these observations open a possible link between CYP46A1
neuroprotective effect and aggregate clearance.
In summary, our ﬁndings reveal a previously unknown
and unexpected role for CYP46A1 in Huntington’s disease
pathogenesis. CYP46A1 prevented cholesterol accumula-
tion in R6/2 mice and displayed neuroprotective effect via
regulation of sterols, more speciﬁcally lanosterol and des-
mosterol (Fig. 7). We have revealed new cholesterol-target-
ing therapeutic strategies in Huntington’s disease, and
Figure 4 Continued
suspension. Note the clasping posture of R6/2 saline (bottom left). (F) Clasping score of the six groups of mice. (C–F) Wild-type saline (n = 11),
wild-type AAVrh10-GFP (n = 6), wild-type AAVrh10-CYP46A1-HA (n = 8), R6/2 saline (n = 16), R6/2 AAVrh10-GFP (n = 5), R6/2 AAVrh10-
CYP46A1-HA (n = 16). Data are represented as mean  SEM, statistical analysis: two-way ANOVA followed by Bonferroni’s post hoc test.
P5 0.05; P5 0.01; P5 0.001, wild-type saline versus R6/2 saline; *P5 0.05; **P5 0.01; ***P5 0.001 R6/2 saline versus R6/2 AAVrh10-
CYP46A1-HA; §P5 0.05; §§P5 0.01; R6/2 AAVrh10-GFP versus R6/2 AAVrh10-CYP46A1-HA; ¤P5 0.05; ¤¤P5 0.01; ¤¤¤P5 0.001 wild-type
saline versus R6/2 AAVrh10-CYP46A1-HA; ##P5 0.01; ###P5 0.001; R6/2 saline at 6 and 11 weeks. ns = non-significant.
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Figure 5 CYP46A1-HA expression alleviates neuropathological hallmarks in R6/2 mice. (A) Dorsal striatal sections after double
immunostaining with DARPP32 and haemagglutinin (HA) antibodies in 12-week-old wild-type and R6/2 mice injected with saline or AAVrh10-
CYP46A1-HA. (B) Quantification of medium spiny neuron areas after DARPP32 staining. Histograms are represented as mean area  SEM (n = 5
independent mice). In each representative sections, 150 positive DARPP32 medium spiny neurons were quantified. Statistical analyses: one-way
ANOVA followed by Bonferroni’s post hoc test. P5 0.001, wild-type (WT) saline compared to R6/2 saline; **P5 0.01, R6/2 saline compared to
R6/2 CYP46A1-HA; ¤P5 0.05, wild-type saline compared to R6/2 CYP46A1-HA. (C) Immunohistochemical staining with the EM48 antibody in a
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Figure 5 Continued
dorsal striatal section of R6/2 mice (12 weeks old) injected with saline (left) or AAVrh10-CYP46A1-HA (right). (D) A threshold of aggregate
intensity was applied to R6/2 mice and AAVrh10-CYP46A1-injected mice. Using this threshold, aggregate number was performed and quantified
and normalized to R6/2 saline mice. Histograms are represented as mean  SEM, n = 4–5 for AAVrh10-CYP46A1-HA and saline groups,
respectively. Statistical analyses: unpaired Student’s t-test *P5 0.05. (E) Two dimensional average projection from 3D images of aggregates in
dorsal striatum. Analysis was performed in 3D but images are shown in 2D for easier visualization of intensities. Calibration bar shows the code of
false colours representing the intensities. (F) Cumulative distribution frequency of mean intensities measured in 3D aggregates. (G) Three
dimensional view of Hoechst stained nuclei with EM48 stained aggregates in the dorsal striatum. Note that aggregates are nuclear inclusions, and
that their volumes are decreased in AAvrh10-CYP46A1-HA transduced cells. (H) Aggregate volume was quantified in R6/2 mice injected with
either saline or AAVrh10-CYP46A1. Data are represented as mean  SEM and each dot represents the variance of aggregate volume in each
mouse (n = 4–5 for AAVrh10-CYP46A1 and saline groups, respectively). Mann-Whitney test ***P5 0.001. (I) Cumulative distribution of ag-
gregates volumes. 1400 aggregates were quantified from R6/2-saline mice (at least two striatal section per mouse, n = 5 independent mice) and
900 aggregates from AAVrh10-CYP46A1-HA R6/2 mice (at least two striatal section per mouse, n = 4 independent mice).
Figure 6 Regulation of cholesterol homeostasis by CYP46A1. At the end of the behavioural studies (12 weeks) groups of mice (n = 5–7
per group) were rapidly sacrificed and the striatum from both hemispheres was dissected and flash frozen in liquid nitrogen. (A–E) Sterols and
24S-OHC levels were measured in the striatum of wild-type and R6/2 mice injected or not with AAVrh10-CYP46A1. Data are represented as
mean  SEM, n = 5–7 for all groups statistical analysis: Mann-Whitney test *P5 0.05, **P5 0.01, ***P5 0.001 for wild-type versus R6/2 mice and
##P5 0.01 for wild-type AAVrh10-GFP versus wild-type AAVrh10CYP46A1-HA. (F) Striatal neurons were transfected with cDNA coding 103Q-
HTT and treated with lanosterol, desmosterol, cholesterol, or 24S-OHC (1 mM) for 48 h. Quantification of surviving transfected neurons was
based on Hoechst labelling. Data are expressed as mean  SEM (at least three independent experiments; 100 transfected neurons per condition
and per experiment). One-factor ANOVA followed by Bonferroni’s post hoc test was performed *P5 0.05; **P5 0.01; ***P5 0.001.
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presumably in other neurodegenerative diseases where dys-
regulation of cholesterol homeostasis has been clearly iden-
tiﬁed. This study paves the way to restore CYP46A1
expression in the striatum/putamen and caudate of
Huntington’s disease patients by direct injection of viral
vector (AAV or lentivirus), as in Parkinson’s disease (Palﬁ
et al., 2014).
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